📰 Electrocore Inc News
Page 3 - Electrocore Inc News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Electrocore Inc. Real-time updates on events, politics, business and more.
February 4, 2022
/PRNewswire/ -- The "Global Bioelectric Medicine Market 2020-2030 by Product Type, End User, and Region: Trend Forecast and Growth Opportunity" report has been...
January 20, 2022
Major neurostimulation devices market players include Abbott, Boston Scientific, IntraPace, Laborie, LivaNova, Medtronic, Neuronetics, SPR Therapeutics, Cyberonics, ElectroCore Inc., Aleva Neurotherapeutics
January 20, 2022
/PRNewswire/ -- The neurostimulation devices market size is anticipated to record a valuation of USD 13.6 billion by 2027, according to the most recent study...
January 20, 2022
/PRNewswire/ -- The neurostimulation devices market size is anticipated to record a valuation of USD 13.6 billion by 2027, according to the most recent study...
October 1, 2021
The Peripheral Nerve Stimulators Market to glaze at a CAGR of 6.9% Annually through 2019
September 30, 2021
The global Neurostimulation Devices market is expected to witness significant growth due to the upsurge in chronic diseases, rising shift from...
May 24, 2021
/PRNewswire/ -- The "Global Neurostimulation Technologies Market 2021-2026" report has been added to ResearchAndMarkets.coms offering. The global...
April 29, 2021
Share this article LAS VEGAS, April 29, 2021 /PRNewswire/ -- DelveInsights Endoscopy Fluid Management Systems Market Insights, Competitive Landscape and Market Forecast -2026 provides the current and forecast market of the Endoscopy Fluid Management Systems and comprises of market trends and key competitors of Endoscopy Fluid Management Systems. DelveInsight estimated the market to grow at a steady CAGR over the study period of 2018 – 2026. Endoscopy helps surgeons and clinicians to prop...
April 5, 2021
GammaCore Sapphire will be distributed in Canada by RSK Medical Inc, under an exclusive distribution agreement announced in January this year. The initial term of the agreement is three years. In February this year, the FDA approved an expanded label of gammaCore nVNS to include the acute and preventive treatment of migraine in adolescents between 12 and 17. GammaCore non-invasive vagus nerve stimulator is a non-invasive, hand-held medical therapy applied at the neck as an adjunctive the...
March 1, 2021
The Australian Therapeutic Goods Administration has approved ElectroCore Inc's (NASDAQ: ECOR) gammaCore Sapphire family of products, ...